Package Leaflet: Information for the Patient
Ilmago0.5 mg/0.4 mg hard capsules
Dutasteride/tamsulosin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Dutasteride/tamsulosin hydrochloride is used in men to treat an enlarged prostate (benign prostatic hyperplasia) - a non-cancerous growth of the prostate caused by overproduction of a hormone called dihydrotestosterone, in patients already controlled with dutasteride and tamsulosin administered at the same time.
This medicine is a combination of two different medicines called dutasteride and tamsulosin. Dutasteride belongs to a group of medicines called 5-alpha reductase inhibitors and tamsulosin belongs to a group of medicines called alpha blockers.
As the prostate grows, it can cause urinary problems such as difficulty in the flow of urine and a need to urinate more frequently. It can also cause the stream of urine to be weaker. If benign prostatic hyperplasia is not treated, there is a risk that the flow of urine will be completely blocked (acute urinary retention). This requires immediate medical treatment. In some cases, surgery may be necessary to reduce the size of the prostate or to remove it.
Dutasteride reduces the production of dihydrotestosterone, which helps to reduce the size of the prostate and relieve symptoms. This will reduce the risk of acute urinary retention and the need for surgery. Tamsulosin acts by relaxing the muscles of the prostate, making it easier to urinate and quickly improving symptoms.
Do not take Ilmago:
Consult your doctorif you think you are in any of these situations.
This medicine is only for men. It must not be taken by women, children, or adolescents.
Warnings and precautions
Consult your doctor before starting to take this medicine:
Using Ilmago with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This includes any medicines bought without a prescription.
Do not take Ilmago with these medicines:
It is not recommended to take Ilmago with these medicines:
Certain medicines may interact with dutasteride/tamsulosin, which can increase the risk of you experiencing side effects. Some of these medicines are:
Tell your doctorif you are taking any of these medicines.
Taking Ilmago with food and drinks
You should take this medicine 30 minutes after the same meal each day.
Do not take this medicine with alcohol. Alcohol may worsen the side effects of this medicine.
Pregnancy, breast-feeding, and fertility
Pregnant women (or those who may be pregnant) should avoid contact with the broken capsules. Dutasteride is absorbed through the skin and may affect the normal development of a male baby. This risk is especially important during the first 16 weeks of pregnancy.
Use a condom during sexual intercourse. Dutasteride has been found in the semen of men taking dutasteride/tamsulosin. If your partner is pregnant or thinks she may be pregnant, she should avoid exposure to your semen.
Dutasteride/tamsulosin has been shown to decrease sperm count, motility, and semen volume. This may reduce male fertility.
Consult your doctorif a pregnant woman has been in contact with dutasteride/tamsulosin.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
Some people may experience dizziness during treatment with this medicine, which may affect their ability to drive or operate machinery safely.
Do not drive or operate machineryif you are affected in this way.
This medicine contains soybean lecithin.
This medicine contains soybean lecithin, which may contain soybean oil. It must not be used in case of peanut or soy allergy.
Follow exactly the instructions of administration of this medicine indicated by your doctor. If you are in doubt, consult your doctor or pharmacist again.
If you do not take this medicine regularly, the control of your PSA levels may be affected.
What dose should you take
The recommended dose is one capsule once a day, 30 minutes after the same meal each day.
How to take it
The capsules should be swallowed whole, with water. Do not chew or open the capsules. Contact with the contents of the capsules can irritate your mouth or throat.
If you take more Ilmago than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take this medicine
Do not take a double dose to make up for forgotten doses. Take the next dose at the usual time.
Do not stop taking this medicine
Do not stop taking this medicine without consulting your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reaction
The symptoms of an allergic reaction can include:
Contact your doctor immediately if you experience any of these symptoms and stop taking this medicine.
Dizziness, fainting, and fainting spells
This medicine can cause dizziness, fainting, and, in rare cases, fainting spells. You should be careful when getting up quickly after sitting or lying down, especially if you have to get up during the night, until you know how this medicine affects you. If you feel dizzy or faint during treatment, sit or lie down until these symptoms have disappeared.
Severe skin reactions
The signs of severe skin reactions can include:
Contact your doctor immediately if you have these symptoms and stop using this medicine.
Common side effects (may affect more than 1 in 10 people)
*In a small number of people, some of these side effects may continue after stopping this medicine.
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Other side effects
Frequency cannot be estimated from the available data:
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
Store below 25°C.
After first opening of the container: 90 days.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Composition of Ilmago
Hard capsule shell:iron oxide black (E172), iron oxide red (E172), titanium dioxide (E171), iron oxide yellow (E172), gelatin.
Soft capsule shell:
Contents of the soft capsule shell:propylene glycol monocaprylate, butylhydroxytoluene (E321).
Soft capsule shell:gelatin, glycerol (E422), titanium dioxide (E171).
Tamsulosin pellets:methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 percent (also contains polysorbate 80 and sodium lauryl sulfate), microcrystalline cellulose (E460), dibutyl sebacate, polysorbate 80 (E433), colloidal hydrated silica, calcium stearate.
Black ink:shellac (E904), iron oxide black (E172), propylene glycol (E1520), concentrated ammonia solution (E527), potassium hydroxide (E525).
Appearance of the product and contents of the pack
This medicine is presented in hard capsules, oblong, No. 0EL, with a brown body and a beige cap, printed with C001 in black ink.
Ilmago is available in high-density polyethylene (HDPE) bottles of 30 capsules.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Laboratorios Salvat, S.A.
C/ Gall, 30-36 - 08950
Esplugues de Llobregat
Barcelona - Spain
Manufacturer:
Laboratorios LEÓN FARMA, SA
Navatejera Industrial Estate
C/La Vallina, s/n - 24193 Navatejera - León
Spain
Date of last revision of this leaflet: January 2019
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
The average price of ILMAGO 0.5 mg/0.4 mg HARD CAPSULES in October, 2025 is around 20.15 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.